Longeveron Inc. (NASDAQ:LGVN) Short Interest Update

Longeveron Inc. (NASDAQ:LGVN) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 733,500 shares, a decrease of 28.8% from the August 15th total of 1,030,000 shares. Approximately 16.1% of the shares of the stock are sold short. Based on an average trading volume of 10,480,000 shares, the short-interest ratio is presently 0.1 days.

Longeveron Stock Down 1.0 %

Shares of LGVN stock traded down $0.02 during trading hours on Monday, reaching $2.06. 349,679 shares of the stock traded hands, compared to its average volume of 4,635,396. The firm has a market capitalization of $13.08 million, a PE ratio of -0.22 and a beta of 0.37. Longeveron has a 1-year low of $0.77 and a 1-year high of $26.70. The business has a fifty day moving average price of $2.74 and a 200 day moving average price of $2.51.

Longeveron (NASDAQ:LGVN) last announced its earnings results on Wednesday, August 14th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.80). The firm had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.53 million. Longeveron had a negative net margin of 1,513.83% and a negative return on equity of 237.57%. Research analysts expect that Longeveron will post -3.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. Renaissance Technologies LLC purchased a new position in Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned approximately 2.31% of Longeveron at the end of the most recent reporting period. Institutional investors own 10.01% of the company’s stock.

Analyst Ratings Changes

LGVN has been the topic of a number of recent research reports. Maxim Group decreased their target price on Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Longeveron in a research report on Wednesday, September 4th.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.